1. Home
  2. Analysis
  3. Fasenra
  4. Onychoclasis

Fasenra and Onychoclasis - a phase IV clinical study of FDA data

Summary:

Onychoclasis is reported as a side effect among people who take Fasenra (benralizumab), especially for people who are female, 60+ old, also take Vitamin C, and have Primary immunodeficiency syndrome.

The phase IV clinical study analyzes which people have Onychoclasis when taking Fasenra. It is created by eHealthMe based on reports of 11,790 people who have side effects when taking Fasenra from the FDA, and is updated regularly.

What is Fasenra?

Fasenra has active ingredients of benralizumab. eHealthMe is studying from 11,805 Fasenra users. Check the latest studies of Fasenra.

What is Onychoclasis?

Onychoclasis (breaking of the nails) is found to be associated with 615 drugs and 607 conditions by eHealthMe. Check the latest studies of Onychoclasis.

On Jul, 27, 2026

11,790 people reported to have side effects when taking Fasenra.
Among them, 13 people (0.11%) have Onychoclasis.

Could Fasenra cause Onychoclasis?

Among these 13 people:

What is the gender of people who have Onychoclasis when taking Fasenra? *

  • female: 100 %
  • male: 0.0 %

What is the age of people who have Onychoclasis when taking Fasenra? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

What are other drugs people take besides Fasenra? *

  1. Vitamin C: 9 people, 69.23%
  2. Zyrtec: 8 people, 61.54%
  3. Singulair: 8 people, 61.54%
  4. Belsomra: 8 people, 61.54%
  5. Calcium: 8 people, 61.54%
  6. Epipen: 8 people, 61.54%
  7. Forteo: 8 people, 61.54%
  8. Lyrica: 8 people, 61.54%
  9. Magnesium: 8 people, 61.54%
  10. Melatonin: 8 people, 61.54%

What are other side effects people have besides Onychoclasis? *

  1. Pain: 13 people, 100.00%
  2. Lung Disorder (lung disease): 12 people, 92.31%
  3. Inflammation: 8 people, 61.54%
  4. Movement Disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness): 8 people, 61.54%
  5. Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 8 people, 61.54%
  6. Herpes Zoster: 8 people, 61.54%
  7. Skin Discoloration: 8 people, 61.54%
  8. Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 7 people, 53.85%
  9. Head Injury: 6 people, 46.15%
  10. Itching: 6 people, 46.15%

What are the existing conditions these people have? *

  1. Primary Immunodeficiency Syndrome: 8 people, 61.54%
  2. Immunodeficiency Common Variable: 6 people, 46.15%
  3. Dyspnea (difficult or laboured breathing): 5 people, 38.46%
  4. Asthma: 5 people, 38.46%
  5. Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Fasenra and have Onychoclasis?

- Check whether Onychoclasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fasenra:

Onychoclasis treatments and more:

How severe was Onychoclasis and when was it recovered:

Expand to all the drugs that have ingredients of benralizumab:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Fasenra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Onychoclasis:

Browse all the conditions that are associated with Onychoclasis:

How the study uses the data?

The study uses data from the FDA. It is based on benralizumab (the active ingredients of Fasenra) and Fasenra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.